Plenary Session Abstracts
Author(s): Jorge Cortes, et al. ABSTRACT
This is the first report of the results of the QuANTUM-R trial, showing that single-agent Q significantly prolonged OS in pts with R/R FLT3-ITD–mut AML compared with SC. These pivotal data confirm the efficacy and safety of Q and the value of targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3i. These results represent the first positive phase 3 trial to demonstrate improved OS with FLT3i in the R/R FLT3-ITD–mut AML setting.